Drug Profile


Latest Information Update: 02 Feb 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Penn State College of Medicine
  • Developer SuperGen
  • Class Antihyperglycaemics; Antihyperlipidaemics; Antihypertensives; Pyrazines; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Diabetic complications; Hyperlipidaemia; Type 2 diabetes mellitus

Most Recent Events

  • 16 Nov 2006 Pyrazinoguanidine is still available for licensing (
  • 16 Mar 2005 Phase-II clinical trials in Diabetes mellitus in USA (PO)
  • 03 Feb 2004 Pyrazinoguanidine is still available for licensing (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top